SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as its dedicated community relentlessly builds a unique permissionless brand, marked by ongoing real-world product development including Kendu Spice and diverse entertainment initiatives. This bullish, active community is consistently recognized across crypto platforms for its 

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging on the back of severe cold weather forecasts, including polar vortex threats, driving expectations for increased natural gas demand and significant storage withdrawals across the U.S. and Europe. The community is actively discussing a potential short squeeze amid rallying natural gas futures, though many are also highlighting the commodity's notorious volatility and the potential for a swift reversal.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense investor scrutiny following its recent earnings report, with the stock experiencing significant after-hours volatility despite an earnings beat. Community sentiment is largely divided, balancing the long-term strategic potential of the proposed Warner Bros. Discovery acquisition and its associated intellectual property against concerns over a pause in share buybacks and a cautious outlook. Discussions are heavily focused on whether current price levels represent a significant buying opportunity or signal further downside amidst an evolving competitive streaming environment.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst significant downward pressure, pushing its RSI to historically oversold levels reminiscent of major market downturns and sparking intense debate among traders. While many in the community point to technical breakdowns and broader geopolitical concerns, others anticipate a sharp rebound ahead of upcoming earnings, citing strong iPhone demand and a strategic AI roadmap. This creates a sharply divided sentiment on whether the current dip is a buying opportunity or signals further downside.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial data for its oral eczema drug, soquelitinib, which showed significant skin improvement and a favorable safety profile, even in patients resistant to other therapies. The community is buzzing about its potential as a game-changer in a large market, leading to speculation about future partnerships or a buyout, though some are anticipating a potential share offering following the rapid appreciation.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing heightened trading activity as the community awaits the anticipated finalization of the TikTok U.S. deal while simultaneously reacting to news of a bondholder lawsuit citing undisclosed AI infrastructure debt. Investors are sharply divided, debating whether Oracle's extensive cloud and AI investments will propel future growth or if its increasing debt burden makes it a significant risk.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention following its strategic partnership with Noveon Magnetics to establish a domestic U.S. supply chain for rare earth permanent magnets, a move strongly supported by broader geopolitical initiatives to reduce reliance on foreign supply. The community is keenly anticipating the upcoming quarterly results for further insights, viewing Lynas as a crucial player positioned to benefit from the tightening global rare earths market amidst increasing demand and strategic government focus on critical minerals.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending due to a strategic private placement by Medtronic complementing a recent public offering, sparking significant community speculation about potential future upside and acquisition. This excitement is further fueled by the company's recent commencement of its pivotal DurAVR heart valve trial, with many viewing the stock as currently undervalued.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is actively trending as the community highlights its strategic moves to dominate rare earth production outside China, including a significant acquisition and an updated feasibility study confirming strong economics for its processing expansion. Investors are discussing this as a transformational step towards securing critical minerals for clean energy and AI, reinforcing U.S. energy independence, though some debate its valuation after a rapid run.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is seeing heightened discussion driven by speculation surrounding Berkshire Hathaway's stake and a recent analyst downgrade, amplifying concerns about competitive pressures and declining sales. Despite these headwinds, many in the community view the current price as a "buying opportunity," citing its strong dividend, defensive sector appeal, and the potential value unlock from its planned company split and new CEO appointment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen analysts that are covering the stock, MarketBeat reports. One...

Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE

Campbell & CO Investment Adviser LLC grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 629.1% during the third quarter, according to its most recent 13F filing with...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

SG Americas Securities LLC Purchases Shares of 125,429 Ultragenyx Pharmaceutical Inc. $RARE

SG Americas Securities LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the third quarter, according to the company in its most recent disclosure with the...

What is HC Wainwright's Estimate for RARE FY2025 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research...

HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $60.00

HC Wainwright cut their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $60.00 and set a "buy" rating for the company in a research report on Monday...

Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Guggenheim cut their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a "buy" rating for the company in a report on Monday...

Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00

Bank of America dropped their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a "buy" rating on the stock in a research note on Friday...

RARE Rises on Completion of Rolling Submission for AAV Gene Therapy

Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

RARE
Ultragenyx Pharmaceutical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RARE News

RAREUltragenyx Pharmaceutical Inc